Lacki J K, Müller-Ruchholtz W, Mackiewicz S H
Department of Rheumatology, University Medical School, Poznań, Poland.
Arch Immunol Ther Exp (Warsz). 1997;45(4):285-8.
In the present study, in order to get a better insight into the mechanism of action of cyclophosphamide (CY) in rheumatoid arthritis (RA), we monitored the changes in lymphocytes' expression of leukocyte function associated antigen 1 (LFA-1). A group of 28 patients with refractory severe RA were treated with CY and methylprednisolone (MO) intravenously. Using flow cytometry we evaluated the changes in LFA-1 molecule expression on peripheral lymphocytes. In the analyzed group of patients the proportion of LFA-1 "dim" cells was reduced. After the treatment the ratio was partly normalized. Twelve months after cessation of the therapy high proportion of LFA-1 "dim" was observed only among CY/MP treated patients. The changes were related to clinical improvement. Based on the obtained data, it seems, that the treatment affecting the expression of LFA-1 may slow down lymphocyte migration and by that limit chronic inflammation within the synovium.
在本研究中，为了更深入了解环磷酰胺（CY）在类风湿关节炎（RA）中的作用机制，我们监测了淋巴细胞白细胞功能相关抗原1（LFA-1）表达的变化。一组28例难治性重度RA患者接受了CY和甲泼尼龙（MO）静脉注射治疗。我们使用流式细胞术评估外周淋巴细胞上LFA-1分子表达的变化。在分析的患者组中，LFA-1“低表达”细胞的比例降低。治疗后该比例部分恢复正常。治疗停止12个月后，仅在CY/MP治疗的患者中观察到高比例的LFA-1“低表达”。这些变化与临床改善相关。基于获得的数据，似乎影响LFA-1表达的治疗可能会减缓淋巴细胞迁移，从而限制滑膜内的慢性炎症。
